High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy

Nimotuzumab (h-R3) is a humanized monoclonal antibody that is safe to use against epidermal growth factor receptor (EGFR). However, the available information is insufficient about the dose effect of monoclonal antibody against epidermal growth factor receptor for the treatment of esophageal squamous...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chunyu, Fu, Xiaolong, Cai, Xuwei, Wu, Xianghua, Hu, Xichun, Fan, Min, Xiang, Jiaqing, Zhang, Yawei, Chen, Haiquan, Jiang, Guoliang, Zhao, Kuaile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699509/
https://www.ncbi.nlm.nih.gov/pubmed/26766917
http://dx.doi.org/10.2147/OTT.S89592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699509/
https://www.ncbi.nlm.nih.gov/pubmed/26766917
http://dx.doi.org/10.2147/OTT.S89592

Ejemplares similares